Skip to main content
MANE
NYSE Life Sciences

Veradermics Secures $294.8M IPO, Extends Runway to 2029, Advances Phase 3 Hair Loss Trials

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$64
Mkt Cap
$2.447B
52W Low
$32
52W High
$69.41
52W Position info
100% above low
Off High info
7.8% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Veradermics announced the closing of an upsized $294.8 million IPO, securing funding into 2029, alongside significant progress in its Phase 3 clinical trials for VDPHL01 and a key commercial leadership appointment.


Key Events · Financing and Capital Events · MANE

  • Upsized IPO Closed

    Veradermics successfully closed an upsized initial public offering in February 2026, raising approximately $294.8 million in gross proceeds.

  • Extended Cash Runway

    The IPO proceeds, combined with existing cash, are expected to fund operations into 2029, covering multiple Phase 3 readouts and the anticipated commercial launch of VDPHL01, if approved.

  • Phase 3 Enrollment Completed

    Enrollment has been completed for two pivotal Phase 3 trials (Study 302 and Study 304) of VDPHL01 for male pattern hair loss, with topline data expected in the first half and second half of 2026, respectively.

  • Key Commercial Hire

    Mark Neumann, a biopharmaceutical commercial leader with over 30 years of experience launching blockbuster therapies, was appointed Chief Commercial and Strategy Officer in December 2025.


Analysis · MANE · Life Sciences

This 8-K details multiple highly positive developments for Veradermics, significantly de-risking its financial position and advancing its lead clinical program. The successful closing of an upsized $294.8 million IPO provides substantial capital, extending the company's cash runway into 2029. This funding is critical for a clinical-stage biotech, enabling it to progress through multiple anticipated Phase 3 readouts and a potential commercial launch of VDPHL01. The completion of enrollment in two pivotal Phase 3 trials for male pattern hair loss, with topline data expected in 2026, marks crucial progress towards regulatory submission. Furthermore, the appointment of a seasoned Chief Commercial and Strategy Officer signals strategic preparation for the potential market entry of VDPHL01, which is also being developed as the first non-hormonal oral treatment for female pattern hair loss. Investors should monitor the upcoming Phase 3 data readouts as key catalysts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $64.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $32.00 to $69.41. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $125.10 info
Change: -$4.56 (-4%) info
Market Cap: $5.289B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $125.10 info
Change: -$23.34 (-16%) info
Market Cap: $5.289B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $125.10 info
Change: -$17.62 (-12%) info
Market Cap: $5.289B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $125.10 info
Change: -$16.90 (-12%) info
Market Cap: $5.289B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $125.10 info
Change: -$14.23 (-10%) info
Market Cap: $5.289B info